

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP

Moritz Bewarder,^{1*} Dominic Kaddu-Mulindwa,^{1*} Igor Age Kos,^{1*} Vadim Lesan,¹ Gerhard Held,² Viola Poeschel,¹ Lorenz Thurner,¹ Joerg Thomas Bittenbring,¹ Norbert Schmitz,³ Lorenz Truemper,⁴ Michael Pfreundschuh,^{1†} Konstantinos Christofyllakis,¹ Markus Loeffler,⁵ Bettina Altmann^{5#} and Marita Ziepert^{5#}

¹Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar; ²Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern; ³Department of Medicine A, University Hospital Muenster, Muenster; ⁴Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen and ⁵Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany

[†]*Posthumous.*

^{*}*MB, DKM and IAK contributed equally as first authors.*

[#]*BA and MZ contributed equally as senior authors.*

Correspondence:

M. BEWARDER - moritz.bewarder@uks.eu


<https://doi.org/10.3324/haematol.2022.282126>

Supplemental Table 1: Vincristine reduction of patients treated with 6xCHOP-14 + 8xR according to PNP grade (maximum)


PNP grade (maximum)	Number of patients (%)		
	0	1	2, 3
Patients without VCR reduction (n=135*)	78 (76%)	36 (61%)	19 (28%)
Patients with VCR reduction (n=99*)	24 (24%)	23 (39%)	50 (72%)
All patients (n=234*)	102 (44%)	59 (26%)	69 (30%)

* 2/2/4 patients with missing values for PNP


Supplemental Figure 1: Survival outcomes according to received VCR doses. Event-free (A, D), Progression-free (B, E) and Overall survival (C, F) of all 796 patients (A – C) and of 234 patients treated with the best treatment arm 6xCHOP-14 + 8xR (D – F) participating in the RICOVER-60 trial according to their cumulative Vincristine dose (100 %, $\geq 80\%$ - < 100 %, > 50 % - < 80 %, 50 % and < 50 %). Global log-rank p-values are presented.




No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	305	274	254	237	217	149	100	47	16	0	0
>=80% & <100%	84	75	65	56	50	37	20	5	0	0	0
>50% & <80%	104	90	86	82	74	61	36	15	1	0	0
50%	74	67	64	57	52	40	21	6	0	0	0
<50%	61	56	51	49	42	33	15	7	0	0	0




No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	314	279	259	242	222	153	103	49	18	0	0
>=80% & <100%	84	75	65	56	50	37	20	5	0	0	0
>50% & <80%	107	93	89	85	77	64	38	16	1	0	0
50%	76	68	65	58	53	41	21	6	0	0	0
<50%	62	56	51	49	42	33	15	7	0	0	0




No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	348	320	301	288	271	187	123	63	21	0	0
>=80% & <100%	96	89	85	77	69	51	28	7	1	0	0
>50% & <80%	115	108	103	100	90	76	45	18	1	0	0
50%	85	75	70	65	60	46	25	9	2	0	0
<50%	67	62	60	57	53	45	21	10	1	0	0



No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	112	105	101	95	87	60	40	15	0	0	0
>=80% & <100%	21	20	17	14	11	8	4	1	0	0	0
>50% & <80%	23	19	19	18	16	15	9	4	0	0	0
50%	20	18	17	17	15	12	5	2	0	0	0
<50%	18	17	16	14	12	11	4	1	0	0	0




No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	114	106	102	96	88	61	40	15	0	0	0
>=80% & <100%	21	20	17	14	11	8	4	1	0	0	0
>50% & <80%	23	19	19	18	16	15	9	4	0	0	0
50%	21	19	18	18	16	13	5	2	0	0	0
<50%	19	17	16	14	12	11	4	1	0	0	0




No. at risk	0	12	24	36	48	60	72	84	96	108	120
100%	122	116	112	109	101	68	47	20	0	0	0
>=80% & <100%	22	22	21	18	15	10	4	1	0	0	0
>50% & <80%	24	21	21	21	18	17	11	5	0	0	0
50%	23	21	20	19	17	13	5	2	0	0	0
<50%	19	18	18	16	16	16	8	2	0	0	0

Supplemental Figure 2: Influence of VCR reduction on outcomes according to IPI and age groups. Progression-free survival of all 796 patients participating in the RICOVER-60 trial for IPI groups (IPI 1 (A), IPI 2 (B), IPI 3 (C), IPI 4-5 (D)) and age groups (61 - 65 years (E), 66 - 70 years (F), 71 - 75 years (G), 76 - 80 years (H)) is shown. Log-rank p-values are presented. PFS did not differ in patients with reduced vs. not reduced VCR dosage in any IPI group. A PFS difference in favor of patients with reduced VCR doses was observed in the group of patients aged 76 - 80 years.


A




E




B




F




C



G



D



H

